Loading...
•
Dec 31, 2021
Guardant Health Q4 2021 Earnings Report
Guardant Health experienced revenue growth and advancements in clinical testing and screening programs.
Key Takeaways
Guardant Health reported a 38% increase in revenue for Q4 2021, driven by growth in clinical testing and development services. The company also highlighted progress in its ECLIPSE and SHIELD studies and finalized a settlement with Foundation Medicine.
Revenue reached $108 million, a 38% increase compared to Q4 2020.
Clinical test volume increased by 48% and biopharma test volume increased by 36% year-over-year.
ECLIPSE pivotal study for Guardant Shield blood test reached enrollment of 12,750 patients.
First patient enrolled in SHIELD study to validate blood-based assay in lung cancer screening.
Revenue by Segment
Forward Guidance
Guardant Health expects full year 2022 revenue to be in the range of $460 million to $470 million, representing 23% to 26% growth over full year 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...